Full-Text Search:
Home|About CNKI|User Service|中文
Add to Favorite Get Latest Update

A Combination Chemotherapy of Tamoxifen, Verapamil and MFP in the Treatment of 30 cases of Non-Small Cell Lung Cancer

Chen Lei; Zhan Dewen (Tumor Hospital, Medical College of Shontou University, Shantou 515031 )  
(Purpose) To explore the effect of tamoxifen, verapamil and MFP combined chemotherapy for non-small cell lung cancer(NSCLC). (Methods) Sixty patients with NSCIC were randomized to 2 treatment groups: tamoxifen, verapamil and MFP combination chemotherapy(group A), CAP regimen or IEP regimen comination chemetherapy(group B). Their response rates were compared. (Results) By means of comparsion, the overall response rate(CR+ PR) of group A was 43. 3% (13/30) and that of group B was 26. 7% (8/30). Toxicity effec of chetnoherapy in group A was slight and quaity of life was better than that of group B 1-year survival rate of group A was 60. 0% (18/30), group B 23. 3% (7/30). The statistical edpeis showed marked significant difhant(P<0. 05). (Concluaions) The results showed that tamoxifen, verapamil combined with MFP chmotherapy for non-small cell lung cancer is effeclive.
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©CNKI All Rights Reserved